Publications by authors named "Giulia Rizzuto"

Claim this Profile
S
Severe Activity of Inflammatory Bowel Disease is a Risk Factor for Severe COVID-19.
Fabio Salvatore Macaluso, Alessandra Giuliano, Walter Fries, Anna Viola, Alfredo Abbruzzese, Giulia Rizzuto

Inflamm Bowel Dis· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effectiveness and safety of an on-demand ferric carboxymaltose infusion strategy in patients with inflammatory bowel disease: a real world experience.
Mauro Grova, Federica Crispino, Marcello Maida, Sara Renna, Mariella Mannino, Giulia Rizzuto

Eur J Gastroenterol Hepatol· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SPOSAB ABP 501: A Sicilian Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Adalimumab Biosimilar ABP 501.
Fabio Salvatore Macaluso, Maria Cappello, Anita Busacca, Walter Fries, Anna Viola, Giulia Rizzuto

J Gastroenterol Hepatol· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Blood-based prognostic biomarkers in Crohn's Disease patients on biologics: a promising tool to predict endoscopic outcomes.
Federica Crispino, Mauro Grova, Marcello Maida, Sara Renna, Filippo Mocciaro, Giulia Rizzuto

Expert Opin Biol Ther· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The SPOSIB SB2 Sicilian Cohort: Safety and Effectiveness of Infliximab Biosimilar SB2 in Inflammatory Bowel Diseases, Including Multiple Switches.
Fabio Salvatore Macaluso, Walter Fries, Anna Viola, Andrea Centritto, Maria Cappello, Giulia Rizzuto

Inflamm Bowel Dis· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A propensity score weighted comparison of vedolizumab and adalimumab in Crohn's disease.
Fabio Salvatore Macaluso, Marco Ventimiglia, Walter Fries, Anna Viola, Aldo Sitibondo, Giulia Rizzuto

J Gastroenterol Hepatol· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A propensity score weighted comparison of Vedolizumab, Adalimumab, and Golimumab in patients with ulcerative colitis.
Fabio Salvatore Macaluso, Marco Ventimiglia, Walter Fries, Anna Viola, Maria Cappello, Giulia Rizzuto

Dig Liver Dis· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effectiveness and safety of vedolizumab in biologically naïve patients: A real-world multi-centre study.
Fabio Salvatore Macaluso, Walter Fries, Sara Renna, Anna Viola, Marco Muscianisi, Giulia Rizzuto

United European Gastroenterol J· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The PROSIT Cohort of Infliximab Biosimilar in IBD: A Prolonged Follow-up on the Effectiveness and Safety Across Italy.
Alessandro Armuzzi, Gionata Fiorino, Angela Variola, Natalia Manetti, Walter Fries, Giulia Rizzuto

Inflamm Bowel Dis· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Propensity Score-matched Comparison of Infliximab and Adalimumab in Tumour Necrosis Factor-α Inhibitor-naïve and Non-naïve Patients With Crohn's Disease: Real-Life Data From the Sicilian Network for Inflammatory Bowel Disease.
Fabio Salvatore Macaluso, Walter Fries, Antonio Carlo Privitera, Maria Cappello, Sebastiano Siringo, Giulia Rizzuto

J Crohns Colitis· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Letter: SPOSIB SB2-a Sicilian prospective observational study of IBD patients treated with infliximab biosimilar SB2.
Fabio Salvatore Macaluso, Maria Cappello, Enrica Giuffrida, Walter Fries, Andrea Centritto, Giulia Rizzuto

Aliment Pharmacol Ther· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The real-world effectiveness of vedolizumab on intestinal and articular outcomes in inflammatory bowel diseases.
Fabio Salvatore Macaluso, Rosalba Orlando, Walter Fries, Mariangela Scolaro, Antonio Magnano, Giulia Rizzuto

Dig Liver Dis· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Addition of an Immunosuppressant After Loss of Response to Anti-TNFα Monotherapy in Inflammatory Bowel Disease: A 2-Year Study.
Fabio Salvatore Macaluso, Chiara Sapienza, Marco Ventimiglia, Sara Renna, Giulia Rizzuto

Inflamm Bowel Dis· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tolerability profile of thiopurines in inflammatory bowel disease: a prospective experience.
Fabio Salvatore Macaluso, Sara Renna, Marcello Maida, Mariangela Dimarco, Chiara Sapienza, Giulia Rizzuto

Scand J Gastroenterol· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mycophenolate mofetil is a valid option in patients with inflammatory bowel disease resistant to TNF-α inhibitors and conventional immunosuppressants.
Fabio Salvatore Macaluso, Marcello Maida, Sara Renna, Emanuele Orlando, Marco Affronti, Giulia Rizzuto

Dig Liver Dis· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The PROSIT-BIO Cohort: A Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Infliximab Biosimilar.
Gionata Fiorino, Natalia Manetti, Alessandro Armuzzi, Ambrogio Orlando, Angela Variola, Giulia Rizzuto

Inflamm Bowel Dis· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Six year adalimumab efficacy in steroid-dependent Crohn's disease patients: A prospective single-center real life study.
Ambrogio Orlando, Sara Renna, Filippo Mocciaro, Maria Cappello, Marco Giunta, Giulia Rizzuto

Dig Liver Dis· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Selective Use of Combination Therapy in Patients With Infliximab-resistant Inflammatory Bowel Disease: Data From a Tertiary Referral Center.
Ambrogio Orlando, Sara Renna, Giulia Rizzuto, Emanuele Orlando, Marco Affronti

Clin Gastroenterol Hepatol· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cyclosporine or infliximab as rescue therapy in severe refractory ulcerative colitis: early and long-term data from a retrospective observational study.
Filippo Mocciaro, Sara Renna, Ambrogio Orlando, Giulia Rizzuto, Emanuele Sinagra

J Crohns Colitis· July 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Splenic tuberculosis in a patient with Crohn's disease on infliximab: case report.
Maria Cappello, Claudia Randazzo, Giulia Rizzuto, Celestino Bonura, Gaetano Di Vita

Inflamm Bowel Dis· March 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis